High-Dose Etoposide, Cyclophosphamide and Total Body Irradiation with Allogeneic Bone Marrow Transplantation for Resistant Acute Myeloid Leukemia: A Study by the North American Marrow Transplant Group

References

• Vogler W.R., Velez-Garcia E., Weiner R.S., Flaum M.A., Bartolucci A.A., Omura G.A., Gerber M.C., Banks P. L. C. A phase III trial comparing idarubicin and daunorubicin in combination with cytarabine in acute myelogenous leukemia: A Southeastern Cancer Study Group Study. J. Clin. Oncol. 1992; 10: 1103
   PubMed Web of Science ®Google Scholar
• Schiller G.J., Nimer S.D., Territo M.C., Ho W.G., Champlin R.E., Gajewski J.L. Bone marrow transplantation versus high-dose cytarabine-based consolidation chemotherapy for acute myelogenous leukemia in first remission. J. Clin. Oncol 1992; 10: 41
   PubMed Web of Science ®Google Scholar
• Clift R.A., Buckner C.D., Appelbaum F.R., Schoch G., Petersen F.B., Bensinger W.I., Sanders J., Sullivan K.M., Storb R., Singer J., Hansen J.A., Thomas E.D. Allogeneic marrow transplantation during untreated first relapse of acute myeloid leukemia. J. Clin. Oncol. 1992; 10: 1723
   PubMed Web of Science ®Google Scholar
• Copelan E.A., Biggs J.C., Thompson J.M., Crilley P., Szer J., Klein J.P., Kapoor N., Avalos B.R., Cunningham I., Atkinson K., Downs K., Harmon G.S., Daly M.B., Brodsky I., Bulova S.I., Tutschka P.J. Treatment for acute myelocytic leukemia with allogeneic bone marrow transplantation following preparation with BuCy2. Blood 1991; 78: 838
   PubMed Web of Science ®Google Scholar
• Geller R.B., Saral R., Piantadosi S., Zahurak M., Vogelsang G.B., Wingard J.R., Ambinder R.F., Beschomer W.B., Braine H.G., Burns W.H., Hess A.D., Jones R.J., May W.S., Rowley S.D., Wagner J.E., Yeager A.M., Santos G.W. Allogeneic bone marrow transplantation after high-dose busulfan and cy-clophosphamide in patients with acute nonlymphocytic leukemia. Blood 1989; 73: 2209
   PubMed Web of Science ®Google Scholar
• Brown R.A., Herzig R.H., Wolff S.N., Frei-Lahr D., Pineiro L., Bolwell B.J., Lowder J.N., Harden E.A., Hande K.R., Herzig G.P. High-dose etoposide and cyclophosphamide without bone marrow transplantation for resistant hematologic malignancy. Blood 1990; 76: 473
   PubMed Web of Science ®Google Scholar
• Fay J., Wolff S., Herzig R., Phillips G., Herzig G. (abstr) Treatment of non-Hodgkin's lymphoma with intensive VP-16, cyclophosphamide, total body radiotherapy and autologous marrow transplantation. Proc., Am. Soc. Clin. Oncol. 1990; 9: 260a
   Google Scholar
• Brown R.A., Wolff S.N., Fay J.W., Pineiro L., Collins R.H., Jr., Lynch J.P., Stevens D., Greer J., Herzig R.H., Herzig G.P. High-dose etoposide, cyclophosphamide, and total body irradiation with allogeneic bone marrow transplantation for patients with acute myeloid leukemia in untreated first relapse: A study by the North American Transplant Group. Blood 1995; 85: 1391
   PubMed Web of Science ®Google Scholar
• Altaian P.L., Dittmer D.S. Handbook of Growth Including Reproduction and Morphologic Development. Federation of American Society of Experimental Biology, Washington, DC 1962
   Google Scholar
• Glucksberg H., Storb R., Fefer A., Buckner C.D., Neiman P.E., Clift R.A., Lemer K.G., Thomas E.D. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HLA-matched sibling donors. Transplantation 1974; 18: 295
   PubMed Web of Science ®Google Scholar
• Shulman H.M., Sullivan K.M., Weiden P.L., McDonald G.B., Striker G.E., Sale G.E., Hackman R., Mang-So T., Storb R., Donnall Thomas E. Chronic graft-versus-host syndrome in man. Am. J. Med. 1980; 69: 204
   PubMed Web of Science ®Google Scholar
• Herzig G.P. Autologous marrow transplantation in cancer therapy. Prog. Hematol. 1981; 12: 1
   PubMedGoogle Scholar
• Wilson W.H., Jain V., Bryant G., Cowan K.H., Carter C., Cottier-Fox M., Goldspiel B., Steinberg S.M., Longo D.L., Wittes R.E. Phase I and II study of high-dose ifosfamide, carboplatin, and etoposide with autologous bone marrow rescue in lymphomas and solid tumors. J. Clin. Oncol. 1992; 10: 1712
   PubMed Web of Science ®Google Scholar
• Kaplan E.L., Meier P. Nonparametric estimation from incomplete observations. J. Am. Sat. Assoc 1958; 53: 457
   Web of Science ®Google Scholar
• Mantel N. Evaluation of survival data and two rank order statistics arising in its consideration. Cancer Chemother. Rep. 1966; 50: 163
   PubMedGoogle Scholar
• Cox D.R. Regression models and life tables. J. R. Stat. Soc. (B) 1972; 34: 187
   Web of Science ®Google Scholar
• Pipkin F.B. Medical Statistics Made Easy. Churchill-Livingstone, New York, NY 1984; 32, 52
   Google Scholar
• Sullivan K.M., Storb R., Buckner C.D., Fefer A., Fisher L., Weiden P.L., Witherspoon R.P., Appelbaum F.R., Banaji M., Hansen J., Martin P., Sanders J.E., Singer J., Thomas E.D. Graft-versus-host disease as adoptive immunotherapy in patients with advanced hematologic neoplasms. N. Engl. J. Med. 1989; 320: 828
   PubMed Web of Science ®Google Scholar
• Bortin M.M., Horowitz M.M., Rimm A.A. Progress report from the International Bone Marrow Transplant Registry. Bone Marrow Transplant 1992; 10: 113
   PubMed Web of Science ®Google Scholar
• Gale R.P., Horowitz M.M., Ash R.C., Champlin R.E., Goldman J.M., Rimm A.A., Ringden O., Veum-Stone J.A., Bortin M.M. Identical-twin bone marrow transplants for leukemia. Ann. Intern. Med. 1994; 120: 646
   PubMed Web of Science ®Google Scholar
• Linker C.A., Ries C.A., Damon L.E., Rugo H.S., Wolf J.L. Autologous bone marrow transplantation for acute myeloid leukemia using busulfan plus etoposide as a preparative regimen. Blood 1993; 81: 311
   PubMed Web of Science ®Google Scholar
• Petersen F.B., Lynch M. H. E., Clift R.A., Appelbaum F.R., Sanders J.E., Bensinger W.I., Benyunes M.C., Doney K., Fefer A., Martin P., Storb R., Rowley S., Sullivan K.M., Witherspoon R., Weiden P., Thomas E.D., Fisher L., Hansen J.A., Buckner C.D. Autologous marrow transplantation for patients with acute myeloid leukemia in untreated first relapse or in second complete remission. J. Clin. Oncol 1993; 11: 1353
   PubMed Web of Science ®Google Scholar
• Aurer I., Gale R.P. Are new conditioning regimens for transplants in acute myelogenous leukemia better?. Bone Marrow Transplant 1991; 7: 255
   PubMed Web of Science ®Google Scholar
• Spitzer T.R., Cottier-Fox M., Torrisi J., Cahill R., Greenspan A., Lynch M., Deeg H.J. Escalating doses of etoposide with cyclophosphamide and fractionated total body irradiation or busulfan as conditioning for bone marrow transplantation. Bone Marrow Transplant 1989; 4: 559
   PubMed Web of Science ®Google Scholar
• Bostrom B., Weisdorf D.J., Kim T., Kersey J.H., Ramsay N. K. C. Bone marrow transplantation for advanced acute leukemia: a pilot study of high-energy total body irradiation, cyclophosphamide and continuous infusion etoposide. Bone Marrow Transplant 1990; 5: 83
   PubMed Web of Science ®Google Scholar
• Yau J.C., LeMaistre C.F., Andersson B.S., Huan S.D., Wallerstein R.O., Woo S.Y., Spitzer G., Spinolo J.A., Spencer V., Brunner L.J., Dimopoulos M.A., Jagannath S., Giralt S., Meneghetti C.M., Dicke K.A., Deisseroth A.B. Allogeneic bone marrow transplantation for hematological malignancies following etoposide, cyclophosphamide, and fractionated total body irradiation. Am. J. Hematol. 1992; 41: 40
   PubMed Web of Science ®Google Scholar
• Petersen F.B., Buckner C.D., Appelbaum F.R., Clift R.A., Sanders J.E., Bensinger W.I., Storb R., Witherspoon R.P., Sullivan K.M., Bearman S.I., Flournoy N., Thomas E.D. Busulfan, cyclophosphamide and fractionated total body irradiation as a preparatory regimen for marrow transplantation in patients with advanced hematological malignancies: a phase I study. Bone Marrow Transplant 1989; 4: 617
   PubMed Web of Science ®Google Scholar
• Vaughan W.P., Dennison J.D., Reed E.C., Klassen L., McGuire T.R., Sanger W.G., Kumar P.P., Warkentin P.I., Gordon B.G., Bierman P.J., Coccia P.F., Armitage J.O. Improved results of allogeneic bone marrow transplantation for advanced hematologic malignancy using busulfan, cyclophosphamide and etoposide as cytoreductive and immunosuppressive therapy. Bone Marrow Transplant 1991; 8: 489
   PubMed Web of Science ®Google Scholar
• Blume K.G., Forman S.J., O'Donnell M.R., Doroshow J.H., Krance R.A., Nademanee A.P., Snyder D.S., Schmidt G.M., Fahey J.L., Metter G.E., Hill L.R., Findley D.O., Sniecinski I.J. Total body irradiation and high-dose etoposide: A new preparatory regimen for bone marrow transplantation in patients with advanced hematologic malignancies. Blood 1987; 69: 1015
   PubMed Web of Science ®Google Scholar
• Blaise D., Maraninchi D., Archimbaud E., Reiffers J., Devergie A., Jouet J.P., Milpied N., Attal M., Michallet M., Ifrah N., Kuentz M., Dauriac C., Bordigoni P., Gratecos N., Guilhot F., Guyotat D., Gouvernet J., Gluckman E. Allogeneic bone marrow transplantation for acute myeloid leukemia in first remission: A randomized trial of a busulfan-cytoxan versus cytoxan-total body irradiation as preparative regimen: A report from the Groupe d'Etudes de la Greffe de Moelle Osseuse. Blood 1992; 79: 2578
   PubMed Web of Science ®Google Scholar
• Cullis J.O., Jiang Y.Z., Schwarer A.P., Hughes T.P., Barrett A.J., Goldman J.M. Donor leukocyte infusions for chronic myeloid leukemia in relapse after allogeneic bone marrow transplantation. Blood 1992; 79: 1379
   PubMed Web of Science ®Google Scholar
• Kolb H.J., Mittermuller J., Clemm C., Holler E., Ledderose G., Brehm G., Heim M., Wilmanns W. Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients. Blood 1990; 76: 2462
   PubMed Web of Science ®Google Scholar